JP2024525780A - インターロイキン－２３受容体のペプチド阻害剤 - Google Patents

インターロイキン－２３受容体のペプチド阻害剤 Download PDF

Info

Publication number
JP2024525780A
JP2024525780A JP2024501976A JP2024501976A JP2024525780A JP 2024525780 A JP2024525780 A JP 2024525780A JP 2024501976 A JP2024501976 A JP 2024501976A JP 2024501976 A JP2024501976 A JP 2024501976A JP 2024525780 A JP2024525780 A JP 2024525780A
Authority
JP
Japan
Prior art keywords
inhibitor
interleukin
receptor
peptide
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024501976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525780A5 (https=
Inventor
サン，チェンザオ
ニーランカヴィル，サントーシュ
パッチ，レイモンド，ジェイ．
バロス，ステファニー，エー．
ソマニ，サンディープ
ヘンドリック，チャールズ
ジャン，ジン
ビアンキ，エリザベッタ
コスタンテ，ロベルト
インジェニート，ラファエル
ブランカ，ダニラ
バンダリ，アショク
フレデリック，ブライアン
ダニエル，ジェームズ
チュン トラン，トラン
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
プロタゴニスト セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド, プロタゴニスト セラピューティクス， インコーポレイテッド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2024525780A publication Critical patent/JP2024525780A/ja
Publication of JP2024525780A5 publication Critical patent/JP2024525780A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
JP2024501976A 2021-07-14 2022-07-14 インターロイキン－２３受容体のペプチド阻害剤 Pending JP2024525780A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163221806P 2021-07-14 2021-07-14
US63/221,806 2021-07-14
PCT/US2022/037221 WO2023288028A2 (en) 2021-07-14 2022-07-14 Peptide inhibitors of interleukin-23 receptor

Publications (2)

Publication Number Publication Date
JP2024525780A true JP2024525780A (ja) 2024-07-12
JP2024525780A5 JP2024525780A5 (https=) 2025-07-24

Family

ID=84920532

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024501976A Pending JP2024525780A (ja) 2021-07-14 2022-07-14 インターロイキン－２３受容体のペプチド阻害剤

Country Status (11)

Country Link
US (1) US20240409598A1 (https=)
EP (1) EP4370531A4 (https=)
JP (1) JP2024525780A (https=)
KR (1) KR20240034222A (https=)
CN (1) CN117999274A (https=)
AU (1) AU2022310354A1 (https=)
CA (1) CA3226539A1 (https=)
MX (1) MX2024000762A (https=)
TW (1) TW202332683A (https=)
UY (1) UY39856A (https=)
WO (1) WO2023288028A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
HRP20211448T1 (hr) 2014-05-16 2021-12-24 Protagonist Therapeutics, Inc. Alfa4beta7 integrin tioeter peptidni antagonisti
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7397239B2 (ja) 2020-11-20 2023-12-12 ヤンセン ファーマシューティカ エヌ．ベー． インターロイキン－２３受容体のペプチド阻害剤の組成物
EP4370146A4 (en) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Lipidated peptide inhibitors of the interleukin-23 receptor
EP4652180A2 (en) * 2023-01-16 2025-11-26 Janssen Pharmaceutica NV Peptide inhibitors of interleukin-23 receptor
US20240279281A1 (en) * 2023-01-16 2024-08-22 Janssen Pharmaceutica Nv Peptide Inhibitors of Interleukin-23 Receptor
WO2024155553A1 (en) * 2023-01-16 2024-07-25 Janssen Pharmaceutica Nv Lipidated peptide inhibitors of interleukin-23 receptor
IL322423A (en) * 2023-01-31 2025-09-01 Janssen Pharmaceutica Nv Methods for preparing crystalline peptide inhibitors of the interleukin-23 receptor
CN120826233A (zh) * 2023-03-03 2025-10-21 詹森药业有限公司 用于治疗银屑病的白介素-23受体拮抗剂肽
EP4471048A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471049A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
CN121909205A (zh) 2023-09-08 2026-04-21 赛诺菲 作为选择性il-23受体抑制剂的新型肽
CN121794283A (zh) 2023-09-08 2026-04-03 赛诺菲 作为选择性il-23受体抑制剂的新型肽
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2026026816A1 (zh) * 2024-07-30 2026-02-05 西藏海思科制药有限公司 白介素-23受体的肽抑制剂及其用途
WO2026041110A1 (zh) * 2024-08-22 2026-02-26 上海瀚辰星泰医药科技有限公司 一种多肽化合物及其应用
WO2026046292A1 (zh) * 2024-08-28 2026-03-05 西藏海思科制药有限公司 白介素-23受体的肽抑制剂的药物组合物及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9605027B2 (en) * 2011-06-14 2017-03-28 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
CN107206254B (zh) * 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
US10787490B2 (en) * 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX384213B (es) * 2015-07-15 2025-03-14 Protagonist Therapeutics Inc Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias.
WO2018136646A1 (en) * 2017-01-18 2018-07-26 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2020014646A1 (en) * 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7534382B2 (ja) * 2019-07-10 2024-08-14 プロタゴニスト セラピューティクス， インコーポレイテッド インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
WO2021007433A1 (en) * 2019-07-10 2021-01-14 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3167751A1 (en) * 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Also Published As

Publication number Publication date
AU2022310354A1 (en) 2024-02-29
EP4370531A2 (en) 2024-05-22
KR20240034222A (ko) 2024-03-13
UY39856A (es) 2023-02-28
EP4370531A4 (en) 2025-09-03
WO2023288028A2 (en) 2023-01-19
TW202332683A (zh) 2023-08-16
CN117999274A (zh) 2024-05-07
MX2024000762A (es) 2024-04-18
US20240409598A1 (en) 2024-12-12
CA3226539A1 (en) 2023-01-19
WO2023288028A3 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
JP2024525780A (ja) インターロイキン－２３受容体のペプチド阻害剤
JP7819087B2 (ja) インターロイキン－２３受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用
JP7441955B2 (ja) インターロイキン２３受容体のペプチド阻害剤および炎症性疾患を治療するためのその使用
US12478617B2 (en) Lipidated peptide inhibitors of interleukin-23 receptor
JP7670605B2 (ja) インターロイキン－２３受容体のペプチド阻害剤および炎症性疾患を治療するためのその使用
JP7534382B2 (ja) インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
JP2024525723A (ja) インターロイキン－２３受容体の二環式ペプチド阻害剤
JP2025134806A (ja) インターロイキン２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
CA2726917A1 (en) Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP5185808B2 (ja) 新たなハイブリッドオリゴマー、それらの製造方法およびそれらを含有する医薬組成物
HK40111925A (zh) 白介素-23受体的脂化肽抑制剂
JP2026503450A (ja) インターロイキン－２３受容体のペプチド阻害剤
EA049310B1 (ru) Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250714